

02/11/2006 10661139.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:06:07 ON 11 FEB 2006

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:06:18 ON 11 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 FEB 2006 HIGHEST RN 873916-87-1
DICTIONARY FILE UPDATES: 9 FEB 2006 HIGHEST RN 873916-87-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10661139.str



```

chain nodes :
16 17 18 19 20 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
5-10 16-17 16-20 16-21 17-18 17-19
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-6 6-7 16-17 16-21 17-18 17-19
exact bonds :
5-9 5-10 8-9 16-20
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:H,Cb,Cy,Hy,Ak

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 23:CLASS

```

L1 STRUCTURE UPLOADED


=> d l1

L1 HAS NO ANSWERS

L1 STR

02/11/2006

10661139.trn



G1 H, Ob, Cy, Hy, Ak.

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:06:40 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 584 TO ITERATE

100.0% PROCESSED 584 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 10231 TO 13129

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 14:06:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 11558 TO ITERATE

100.0% PROCESSED 11558 ITERATIONS


SEARCH TIME: 00.00.01

0 ANSWERS

L3 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10661139a.str



```

chain nodes :
16 17 18 19 20
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
5-10 16-17 16-19 16-20 17-18
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-6 6-7 16-17 16-20 17-18
exact bonds :
5-9 5-10 8-9 16-19
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:H,Cb,Cy,Hy,Ak

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 22:CLASS


```

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 H,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s 14

SAMPLE SEARCH INITIATED 14:07:50 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 584 TO ITERATE

100.0% PROCESSED 584 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 10231 TO 13129

PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s 14 sss full

FULL SEARCH INITIATED 14:07:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 11558 TO ITERATE

100.0% PROCESSED 11558 ITERATIONS


SEARCH TIME: 00.00.01

0 ANSWERS

L6 0 SEA SSS FUL L4

=>

Uploading C:\Program Files\Stnexp\Queries\10661139b.str



```

chain nodes :
16 17 18 19 23
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
5-10 16-17 16-19 17-18 17-23
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-6 6-7 16-17 17-18 17-23
exact bonds :
5-9 5-10 8-9 16-19
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:H,Cb,Cy,Hy,Ak

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS


```

L7 STRUCTURE UPLOADED

```

=> d 17
L7 HAS NO ANSWERS
L7 STR

```



G1 H, Cb, Cy, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l7

SAMPLE SEARCH INITIATED 14:09:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2408 TO ITERATE

83.1% PROCESSED 2000 ITERATIONS

16 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 45217 TO 51103

PROJECTED ANSWERS: 122 TO 648

L8 16 SEA SSS SAM L7

=> s l7 sss full

FULL SEARCH INITIATED 14:10:13 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 47878 TO ITERATE

100.0% PROCESSED 47878 ITERATIONS


SEARCH TIME: 00.00.01

333 ANSWERS

L9 333 SEA SSS FUL L7

=>

Uploading C:\Program Files\Stnexp\Queries\10661139c.str



```

chain nodes :
16 17 18 19 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
5-10 16-17 16-19 17-18 17-22 23-24 23-26 24-25 24-27
ring bonds :
1-2 1-7 2-3 3-4 4-8 5-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15
exact/norm bonds :
5-6 6-7 16-17 17-18 17-22 23-24 24-25 24-27
exact bonds :
5-9 5-10 8-9 16-19 23-26
normalized bonds :
1-2 1-7 2-3 3-4 4-8 7-8 10-11 10-15 11-12 12-13 13-14 14-15
isolated ring systems :
containing 1 : 10 :

```

G1:H,Cb,Cy,Hy,Ak

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS 19:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS


```

L10 STRUCTURE UPLOADED

=> d l10

L10 HAS NO ANSWERS

L10 STR



G1 H, Cb, Cy, Hy, Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l10

SAMPLE SEARCH INITIATED 14:15:23 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 169 TO ITERATE

100.0% PROCESSED 169 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2601 TO 4159

PROJECTED ANSWERS: 7 TO 298

L11 7 SEA SSS SAM L10

=> s l10 sss full

FULL SEARCH INITIATED 14:15:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3157 TO ITERATE

100.0% PROCESSED 3157 ITERATIONS

SEARCH TIME: 00.00.01

123 ANSWERS

L12 123 SEA SSS FUL L10

=> d his

(FILE 'HOME' ENTERED AT 14:06:07 ON 11 FEB 2006)

FILE 'REGISTRY' ENTERED AT 14:06:18 ON 11 FEB 2006

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 0 S L1 SSS FULL

L4 STRUCTURE UPLOADED

02/11/2006 10661139.trn

L5 0 S L4
L6 0 S L4 SSS FULL
L7 STRUCTURE UPLOADED
L8 16 S L7
L9 333 S L7 SSS FULL
L10 STRUCTURE UPLOADED
L11 7 S L10
L12 123 S L10 SSS FULL

=> FIL HCAPLUS
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
673.04	673.25

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 14:15:47 ON 11 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 10 Feb 2006 (20060210/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19
L13 40 L9

=> s 112
L14 2 L12

=> d 114 ibib abs hitstr tot

L14 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:252623 HCAPLUS

DOCUMENT NUMBER: 140:287264

TITLE: Pharmaceutical compositions of phenyl-indole compounds for modulating IgE and inhibiting cellular proliferation

INVENTOR(S): Sircar, Jagadish C.; Ramnauth, Jailall; Richards, Mark L.

PATENT ASSIGNEE(S): Avanir Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 131 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024896	A2	20040325	WO 2003-US30959	20030912
WO 2004024896	A3	20040624		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2498493 AA 20040325 CA 2003-2498493 20030912 US 2004180946 A1 20040916 US 2003-661139 20030912 EP 1537079 A2 20050608 EP 2003-795717 20030912 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK BR 2003014223 A 20050726 BR 2003-14223 20030912 PRIORITY APPLN. INFO.: US 2002-410777P P 20020912 WO 2003-US30959 W 20030912 OTHER SOURCE(S): MARPAT 140:287264 GI				



I



II

AB The present invention is directed to phenylindole based small mol. inhibitors I [L and M independently = H, alkyl, alkoxy, aryl, (un)substituted aryl, hydroxy, halo, amino, alkylamino, etc.; R = H, alkyl, benzyl, 4-fluorobenzyl, and dialkylamino alkyl; R1 and R2 independently = H, (un)substituted-alkyl, -cycloalkyl, -polycyclic aliphatic groups, -Ph, etc.; X = NHCO or CONH] of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. Methods for preparing intermediates for the synthesis of I are given; thus, e.g., II (Ad = 1-adamantyl) was prepared by condensation of

3-bromophenylhydrazine with 4-nitroacetophenone followed by acid catalyzed cyclocondensation to form 2-(4-nitrophenyl)-6-bromo-1H-indole which underwent substitution from the cyano derivative which was converted in three steps to the 2-(4-nitrophenyl)-1H-indole-6-carboxylic acid, then a sequence of amidation, nitro reduction In assays for determining suppression of IgE

response, I produced 50% inhibition at concentration ranges from 1 pM to 100 µM. This invention also relates to phenyl-indole mols. that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small mols. which suppress cytokines and leukocytes.

IT 675821-05-3P 675821-06-4P 675821-07-5P
675821-08-6P 675821-09-7P 675821-10-0P
675821-11-1P 675821-12-2P 675821-13-3P
675821-14-4P 675821-15-5P 675821-16-6P
675821-17-7P 675821-18-8P 675821-19-9P
675821-20-2P 675821-21-3P 675821-22-4P
675821-23-5P 675821-24-6P 675821-25-7P
675821-26-8P 675821-27-9P 675821-28-0P
675821-29-1P 675821-31-5P 675821-33-7P
675821-34-8P 675821-35-9P 675821-36-0P
675821-37-1P 675821-38-2P 675821-39-3P
675821-40-6P 675821-41-7P 675821-42-8P
675821-43-9P 675821-44-0P 675821-45-1P
675821-46-2P 675821-47-3P 675821-48-4P
675821-49-5P 675821-50-8P 675821-51-9P
675821-52-0P 675821-53-1P 675821-54-2P
675821-55-3P 675821-56-4P 675821-57-5P
675821-58-6P 675821-59-7P 675821-60-0P
675821-61-1P 675821-62-2P 675821-63-3P
675821-64-4P 675821-65-5P 675821-66-6P
675821-67-7P 675821-68-8P 675821-69-9P
675821-70-2P 675821-71-3P 675821-72-4P
675821-73-5P 675821-74-6P 675821-75-7P
675821-76-8P 675821-77-9P 675821-78-0P
675821-79-1P 675821-80-4P 675821-81-5P
675821-82-6P 675821-83-7P 675821-84-8P
675821-85-9P 675821-86-0P 675821-87-1P
675821-88-2P 675821-89-3P 675821-90-6P
675821-91-7P 675821-92-8P 675821-93-9P
675821-94-0P 675821-95-1P 675821-96-2P
675821-97-3P 675821-98-4P 675821-99-5P
675822-00-1P 675822-01-2P 675822-02-3P
675822-03-4P 675822-04-5P 675822-05-6P
675822-06-7P 675822-07-8P 675822-08-9P
675822-09-0P 675822-10-3P 675822-11-4P
675822-12-5P 675822-13-6P 675822-14-7P
675822-15-8P 675822-16-9P 675822-17-0P
675822-18-1P 675822-19-2P 675822-20-5P
675822-21-6P 675822-22-7P 675822-23-8P
675822-24-9P 675822-25-0P 675822-26-1P
675822-27-2P 675822-28-3P 675822-29-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylindoles as modulators of IgE response and antitumor agents)


RN 675821-05-3 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-

02/11/2006


10661139.trn

yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 675821-06-4 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-07-5 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675821-08-6 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-09-7 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-10-0 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-11-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-12-2 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-13-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



02/11/2006 10661139.trn


RN 675821-14-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(2-pyridinylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-15-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-16-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-17-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(3-pyridinylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-18-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-19-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(4-pyridinylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-20-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[[4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-21-3 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-22-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-23-5 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-24-6 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-25-7 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-26-8 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(2-methylcyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-27-9 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-28-0 HCAPLUS

CN Tricyclo[3.3.1.1¹³,7]decane-1-carboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-29-1 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]-(9CI) (CA INDEX NAME)




RN 675821-31-5 HCAPLUS

CN Tricyclo[3.3.1.1¹³,7]decane-1-carboxamide, N-[4-[5-
[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-33-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-34-8 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-35-9 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-36-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-37-1 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[[[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]]- (9CI) (CA INDEX NAME)




RN 675821-38-2 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]]- (9CI) (CA INDEX NAME)




RN 675821-39-3 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[[[(4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]]- (9CI) (CA INDEX NAME)




RN 675821-40-6 HCAPLUS

CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]]-4-methyl- (9CI) (CA INDEX NAME)




RN 675821-41-7 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[5-[[2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-42-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[[2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-43-9 HCAPLUS


CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 675821-44-0 HCAPLUS


CN Cycloheptanecarboxamide, N-[4-[5-[[2-methylcyclohexyl)carbonyl]amino]-1H-

indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-45-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[[2-(2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-46-2 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-47-3 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-48-4 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(3,4-dichlorobenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-49-5 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(4-methoxybenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-50-8 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[5-[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-51-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-52-0 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-53-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-54-2 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[5-[[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-55-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[[[4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-56-4 HCAPLUS

CN Cyclohexanecarboxamide, 4-methyl-N-[4-[5-[[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-57-5 HCAPLUS

CN Benzamide, N-[4-[5-[[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-58-6 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[5-[[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-59-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-60-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.3⁰.1³]-undec-1-ylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-61-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(3-pyridinylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-62-2 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[2-[4-[[4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-63-3 HCAPLUS

CN Benzamide, N-[4-[5-[[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-64-4 HCAPLUS

CN Benzamide, 4-chloro-N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 675821-65-5 HCAPLUS

CN Benzamide, 4-chloro-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 675821-66-6 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 675821-67-7 HCAPLUS

CN Benzamide, 4-methoxy-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 675821-68-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-69-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(3-pyridinylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-70-2 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-71-3 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-72-4 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl - (9CI) (CA INDEX NAME)




RN 675821-73-5 HCAPLUS

CN Benzamide, N-[2-[4-[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl - (9CI) (CA INDEX NAME)




RN 675821-74-6 HCAPLUS

CN Benzamide, N-[2-[4-[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl - (9CI) (CA INDEX NAME)




RN 675821-75-7 HCAPLUS

CN Benzamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)




RN 675821-76-8 HCAPLUS

CN Benzamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]-4-chloro- (9CI)
(CA INDEX NAME)


RN 675821-77-9 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[4-[5-[[2-(methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-78-0 HCAPLUS


CN 4-Pyridinecarboxamide, N-[2-[4-[[2-(methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 675821-79-1 HCAPLUS


CN 4-Pyridinecarboxamide, N-[2-[4-[[2-(methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

] -1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-80-4 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-81-5 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-82-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-83-7 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-84-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]- (9CI)
(CA INDEX NAME)


RN 675821-85-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-86-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-87-1 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-methyl-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675821-88-2 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-89-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-90-6 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-91-7 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-92-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-93-9 HCAPLUS

CN Benzamide, 4-methoxy-N-[2-[4-[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-94-0 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-95-1 HCAPLUS

CN Benzamide, 4-methoxy-N-[2-[4-[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-96-2 HCAPLUS

CN Benzamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-97-3 HCAPLUS

CN Benzamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-98-4 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(4-fluorobenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-99-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(4-fluorobenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-00-1 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 675822-01-2 HCAPLUS


CN Benzamide, 4-fluoro-N-[2-[4-[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 675822-02-3 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-[4-[[4-oxotricyclo[3.3.1.3⁷,7]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 675822-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[4-hydroxytricyclo[3.3.1.3⁷,7]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


RN 675822-04-5 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-05-6 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675822-06-7 HCAPLUS

CN Cyclohexanamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-methyl-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-07-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[4-(methoxyimino)tricyclo[3.3.1.3^1,7]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675822-08-9 HCAPLUS

CN Tricyclo[3.3.1.3^1,7]decane-1-carboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-09-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-10-3 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-11-4 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-12-5 HCAPLUS


CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 675822-13-6 HCAPLUS


CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

RN 675822-14-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)


RN 675822-15-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(2-pyridinylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-16-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-17-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-18-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-19-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[4-oxotricyclo[3.3.1.3.3]dec-1-yl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-20-5 HCAPLUS

CN Tricyclo[3.3.1.3.3]decane-1-carboxamide, N-[4-[6-[(tricyclo[3.3.1.3.3]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-21-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[(tricyclo[3.3.1.3.1]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-22-7 HCAPLUS

CN Tricyclo[3.3.1.3.1]decane-1-carboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-23-8 HCAPLUS

CN Tricyclo[3.3.1.3.1]decane-1-carboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-24-9 HCAPLUS


CN Tricyclo[3.3.1.3.1]decane-1-carboxamide, N-[2-[4-[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-25-0 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, 4-oxo-N-[4-[6-
[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl] - (9CI)
(CA INDEX NAME)

RN 675822-26-1 HCAPLUS


CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-
indol-6-yl]-2-methyl - (9CI) (CA INDEX NAME)

RN 675822-27-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[[2-methylcyclohexyl)carbonyl]amino]-1H-
indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)


RN 675822-28-3 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[6-[[2-
methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]-4-oxo- (9CI) (CA
INDEX NAME)



RN 675822-29-4 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[6-[[[2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:252465 HCAPLUS

DOCUMENT NUMBER: 140:287262

TITLE: Pharmaceutical compositions of phenyl-indole compounds for modulating I ϵ E and inhibiting cellular proliferation

INVENTOR(S): Sircar, Jagadish C.; Ramnauth, Jailall; Richards, Mark L.

PATENT ASSIGNEE(S): Ayantar Pharmaceuticals, USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024655	A2	20040325	WO 2003-US28145	20030909
W: AE, AG, AL, AM, <u>AN</u> , AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GD, GE, GH, GM, GR, GU, HA, HB, HD, HE, HF, HI, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SR, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VJ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2004180946 A1 20040916 US 2003-661139 20030912


PRIORITY APPLN. INFO.: US 2002-410777P P 20020912

OTHER SOURCE(S): MARPAT 140:287262

GI



I



II

AB The present invention is directed to phenylindole based small mol. inhibitors I [L and M independently = H, alkyl, alkoxy, aryl, (un)substituted aryl, hydroxy, halo, amino, alkylamino, etc.; R = H, alkyl, benzyl, 4-fluorobenzyl, and dialkylamino alkyl; R1 and R2 independently = H, (un)substituted-alkyl, -cycloalkyl, -polycyclic aliphatic groups, -Ph, etc.; X = NHCO or CONH] of the IgE response to allergens, which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. Methods for preparing intermediates for the synthesis of I are given; thus, e.g., II (Ad = 1-adamantyl) was prepared by condensation of 3-bromophenylhydrazine with 4-nitroacetophenone followed by acid catalyzed cyclocondensation to form 2-(4-nitrophenyl)-6-bromo-1H-indole which underwent substitution from the cyano derivative which was converted in three steps to the 2-(4-nitrophenyl)-1H-indole-6-carboxylic acid, then a sequence of amidation, nitro reduction. In assays for determining suppression of IgE

response, I produced 50% inhibition at concentration ranges from 1 pM to 100 μ M. This invention also relates to phenyl-indole mols. that are cellular proliferation inhibitors and thus are useful as anticancer agents. This invention further relates to small mols. which suppress cytokines and leukocytes.

IT 675821-05-3P 675821-06-4P 675821-07-5P
 675821-08-6P 675821-09-7P 675821-10-0P
 675821-11-1P 675821-12-2P 675821-13-3P
 675821-14-4P 675821-15-5P 675821-16-6P
 675821-17-7P 675821-18-8P 675821-19-9P
 675821-20-2P 675821-21-3P 675821-22-4P
 675821-23-5P 675821-24-6P 675821-25-7P
 675821-26-8P 675821-27-9P 675821-28-0P
 675821-29-1P 675821-31-5P 675821-33-7P
 675821-34-8P 675821-35-9P 675821-36-0P
 675821-37-1P 675821-38-2P 675821-39-3P
 675821-40-6P 675821-41-7P 675821-42-8P
 675821-43-9P 675821-44-0P 675821-45-1P
 675821-46-2P 675821-47-3P 675821-48-4P
 675821-49-5P 675821-50-8P 675821-51-9P


675821-52-0P 675821-53-1P 675821-54-2P
675821-55-3P 675821-56-4P 675821-57-5P
675821-58-6P 675821-59-7P 675821-60-0P
675821-61-1P 675821-62-2P 675821-63-3P
675821-64-4P 675821-65-5P 675821-66-6P
675821-67-7P 675821-68-8P 675821-69-9P
675821-70-2P 675821-71-3P 675821-72-4P
675821-73-5P 675821-74-6P 675821-75-7P
675821-76-8P 675821-77-9P 675821-78-0P
675821-79-1P 675821-80-4P 675821-81-5P
675821-82-6P 675821-83-7P 675821-84-8P
675821-85-9P 675821-86-0P 675821-87-1P
675821-88-2P 675821-89-3P 675821-90-6P
675821-91-7P 675821-92-8P 675821-93-9P
675821-94-0P 675821-95-1P 675821-96-2P
675821-97-3P 675821-98-4P 675821-99-5P
675822-00-1P 675822-01-2P 675822-02-3P
675822-03-4P 675822-04-5P 675822-05-6P
675822-06-7P 675822-07-8P 675822-08-9P
675822-09-0P 675822-10-3P 675822-11-4P
675822-12-5P 675822-13-6P 675822-14-7P
675822-15-8P 675822-16-9P 675822-17-0P
675822-18-1P 675822-19-2P 675822-20-5P
675822-21-6P 675822-22-7P 675822-23-8P
675822-24-9P 675822-25-0P 675822-26-1P
675822-27-2P 675822-28-3P 675822-29-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug candidate; preparation of phenylindoles as modulators of IgE response
and antitumor agents)


RN 675821-05-3 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-
yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 675821-06-4 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-
yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-07-5 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675821-08-6 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-09-7 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-10-0 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-11-1 HCAPLUS


CN 2-Pyridinecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-12-2 HCAPLUS


CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)

RN 675821-13-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


RN 675821-14-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(2-pyridinylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-15-5 HCAPLUS


CN 2-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



02/11/2006 10661139.trn


RN 675821-16-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-17-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(3-pyridinylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-18-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-19-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(4-pyridinylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-20-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-21-3 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[5-
[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 675821-22-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.13,7]dec-1-
ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-23-5 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[2-[4-
[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-24-6 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[2-[4-
[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-25-7 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-26-8 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-27-9 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-28-0 HCAPLUS


CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 675821-29-1 HCAPLUS


CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

RN 675821-31-5 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-33-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-34-8 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-35-9 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-36-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-37-1 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-38-2 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(cycloheptylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-39-3 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-40-6 HCAPLUS

CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-41-7 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-42-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-43-9 HCAPLUS

CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675821-44-0 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl- (9CI) (CA INDEX NAME)




RN 675821-45-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl- (9CI) (CA INDEX NAME)




RN 675821-46-2 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]-
(9CI) (CA INDEX NAME)


RN 675821-47-3 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-48-4 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(3,4-dichlorobenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-49-5 HCAPLUS

CN Cycloheptanecarboxamide, N-[2-[4-[(4-methoxybenzoyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-50-8 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-51-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-52-0 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-53-1 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-54-2 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-55-3 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-56-4 HCAPLUS

CN Cyclohexanecarboxamide, 4-methyl-N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-57-5 HCAPLUS

CN Benzamide, N-[4-[5-[[[(4-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-58-6 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-59-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-60-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[tricyclo[3.3.1.1.3,7]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-61-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[[3-pyridinyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-62-2 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[2-[4-[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-63-3 HCAPLUS

CN Benzamide, N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-64-4 HCAPLUS


CN Benzamide, 4-chloro-N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 675821-65-5 HCAPLUS


CN Benzamide, 4-chloro-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-

2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-66-6 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-67-7 HCAPLUS

CN Benzamide, 4-methoxy-N-[4-[5-[[4-methylcyclohexyl]carbonyl]amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-68-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-69-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(3-pyridinylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-70-2 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-71-3 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-72-4 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-73-5 HCAPLUS

CN Benzamide, N-[2-[4-[[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-74-6 HCAPLUS

CN Benzamide, N-[2-[4-[[4-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-75-7 HCAPLUS

CN Benzamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-76-8 HCAPLUS

CN Benzamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 675821-77-9 HCAPLUS

CN Benzamide, 3,4-dichloro-N-[4-[5-[[2-methylcyclohexyl]carbonyl]amino]phenyl]-1H-indol-2-yl- (9CI) (CA INDEX NAME)




RN 675821-78-0 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


RN 675821-79-1 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-[4-[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-80-4 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-81-5 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-82-6 HCAPLUS


CN 2-Pyridinecarboxamide, N-[4-[5-(benzoylamino)-1H-indol-2-yl]phenyl]- (9CI)
(CA INDEX NAME)

RN 675821-83-7 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-84-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]- (9CI)
(CA INDEX NAME)


RN 675821-85-9 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-86-0 HCAPLUS

CN 3-Pyridinecarboxamide, N-[2-[4-[[[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-87-1 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-methyl-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675821-88-2 HCAPLUS

CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)


RN 675821-89-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-90-6 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-91-7 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-92-8 HCAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-93-9 HCAPLUS

CN Benzamide, 4-methoxy-N-[2-[4-[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-94-0 HCAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-[(4-methoxybenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-95-1 HCAPLUS

CN Benzamide, 4-methoxy-N-[2-[4-[[4-(4-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675821-96-2 HCAPLUS

CN Benzamide, N-[2-[4-(benzoylamino)phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-97-3 HCAPLUS

CN Benzamide, N-[2-[4-[(4-chlorobenzoyl)amino]phenyl]-1H-indol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 675821-98-4 HCAPLUS

CN Tricyclo[3.3.1.13,7]decane-1-carboxamide, N-[4-[5-[4-(4-fluorobenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675821-99-5 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[5-[(4-fluorobenzoyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-00-1 HCAPLUS

CN Benzamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-5-yl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 675822-01-2 HCAPLUS

CN Benzamide, 4-fluoro-N-[2-[4-[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675822-02-3 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(4-oxotricyclo[3.3.1.1.3,7]dec-1-yl)carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675822-03-4 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[[4-hydroxytricyclo[3.3.1.1^{3,7}]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME).


RN 675822-04-5 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-05-6 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-[2-(dimethylamino)ethyl]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 675822-06-7 HCAPLUS

CN Cyclohexanamide, N-[4-[5-[(cyclohexylcarbonyl)amino]-1-methyl-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-07-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[[4-(methoxyimino)tricyclo[3.3.1.1^{3,7}]dec-1-yl]carbonyl]amino]phenyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 675822-08-9 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-09-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-10-3 HCAPLUS

CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-11-4 HCAPLUS

CN Cycloheptanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-12-5 HCAPLUS


CN Cyclohexanecarboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 675822-13-6 HCAPLUS


CN Tricyclo[3.3.1.1^{3,7}]decane-1-carboxamide, N-[4-[6-[(cyclohexylcarbonyl)amino]-1H-indol-2-yl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)

RN 675822-14-7 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(tricyclo[3.3.1.1^{3,7}]dec-1-ylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)


RN 675822-15-8 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[(2-pyridinylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-16-9 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-17-0 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-18-1 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-19-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[2-[4-[[4-oxotricyclo[3.3.1.1.3,7]dec-1-yl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-20-5 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[6-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-21-6 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-22-7 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-23-8 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(cycloheptylcarbonyl)amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-24-9 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[2-[4-[(2-methylcyclohexyl)carbonyl]amino]phenyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)




RN 675822-25-0 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, 4-oxo-N-[4-[6-
 [(tricyclo[3.3.1.1.3,7]dec-1-ylcarbonyl)amino]-1H-indol-2-yl]phenyl]- (9CI)
 (CA INDEX NAME)




RN 675822-26-1 HCAPLUS

CN Cyclohexanecarboxamide, N-[2-[4-[(cyclohexylcarbonyl)amino]phenyl]-1H-
 indol-6-yl]-2-methyl- (9CI) (CA INDEX NAME)



RN 675822-27-2 HCAPLUS

CN 2-Pyridinecarboxamide, N-[4-[6-[[[(2-methylcyclohexyl)carbonyl]amino]-1H-
 indol-2-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 675822-28-3 HCAPLUS

CN Tricyclo[3.3.1.1.3,7]decane-1-carboxamide, N-[4-[6-[[[(2-
 methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl]-4-oxo- (9CI) (CA
 INDEX NAME)


02/11/2006

10661139.trn



RN 675822-29-4 HCAPLUS

CN Cyclohexanecarboxamide, 2-methyl-N-[4-[6-[[2-methylcyclohexyl)carbonyl]amino]-1H-indol-2-yl]phenyl] - (9CI) (CA INDEX NAME)



=>

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

78.53

SINCE FILE

ENTRY

-1.50

TOTAL

SESSION

751.78

TOTAL

SESSION

-1.50

STN INTERNATIONAL LOGOFF AT 14:31:51 ON 11 FEB 2006